FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Richard Pazdur, Lynn Howie et al.|Clinical Cancer Research|2018Cited by 133
E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association ConsortiumHisani N. Horne, Laura J. van’t Veer, Stephen M. Hewitt et al.|Scientific Reports|2018Cited by 60